Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma
Status:
Recruiting
Trial end date:
2025-08-20
Target enrollment:
Participant gender:
Summary
This phase II trial compares the usual treatment alone to using immunotherapy (atezolizumab)
plus the usual treatment in treating patients with peritoneal mesothelioma. The usual
treatment consists of surgery or chemotherapy. Chemotherapy drugs, such as carboplatin and
pemetrexed, work in different ways to stop the growth of tumor cells, either by killing the
cells, by stopping them from dividing, or by stopping them from spreading. Bevacizumab is a
monoclonal antibody that may interfere with the ability of tumor cells to grow and spread.
Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune
system attack the cancer, and may interfere with the ability of tumor cells to grow and
spread. Giving atezolizumab with usual treatment may work better than usual treatment alone.